Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “underperform” rating reaffirmed by research analysts at Credit Suisse in a report released on Monday.

Shares of GlaxoSmithKline plc (NYSE:GSK) traded down 0.75% during mid-day trading on Monday, hitting $54.11. The stock had a trading volume of 1,822,113 shares. GlaxoSmithKline plc has a 52 week low of $49.01 and a 52 week high of $56.73. The stock has a 50-day moving average of $54.20 and a 200-day moving average of $53.95. The company has a market cap of $130.2 billion and a P/E ratio of 15.19.

GlaxoSmithKline plc (NYSE:GSK) last released its earnings data on Wednesday, April 30th. The company reported $0.70 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.72 by $0.02. Analysts expect that GlaxoSmithKline plc will post $3.49 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, July 2nd. Separately, analysts at Panmure Gordon downgraded shares of GlaxoSmithKline plc from a “buy” rating to a “hold” rating in a research note on Thursday, June 26th. Finally, analysts at Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, June 20th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company. GlaxoSmithKline plc presently has an average rating of “Hold” and an average price target of $53.50.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.